Several Japanese firms are facing R&D challenges and setbacks in the US, in the form of missed Phase III endpoints, trial recruitment difficulties and a Complete Response Letter.
While many many Japanese firms have shifted much of their commercial and R&D focus to the US, several have recently faced development setbacks that could affect their mid-term outlook in this huge market.
Nippon Shinyaku Co., Ltd.’s Duchenne muscular dystrophy (DMD) therapeutic Viltepso (viltolarsen) recently missed its primary efficacy endpoint in preliminary results from a confirmatory Phase III program designed to support an earlier accelerated approval in the US
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An ‘historic economic prosperity deal’ does not include the sector.
